<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31368485</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2572</StartPage><EndPage>2580</EndPage><MedlinePgn>2572-2580</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awz217</ELocationID><Abstract><AbstractText>Mutations causing amyotrophic lateral sclerosis (ALS) clearly implicate ubiquitously expressed and predominantly nuclear RNA binding proteins, which form pathological cytoplasmic inclusions in this context. However, the possibility that wild-type RNA binding proteins mislocalize without necessarily becoming constituents of cytoplasmic inclusions themselves remains relatively unexplored. We hypothesized that nuclear-to-cytoplasmic mislocalization of the RNA binding protein fused in sarcoma (FUS), in an unaggregated state, may occur more widely in ALS than previously recognized. To address this hypothesis, we analysed motor neurons from a human ALS induced-pluripotent stem cell model caused by the VCP mutation. Additionally, we examined mouse transgenic models and post-mortem tissue from human sporadic ALS cases. We report nuclear-to-cytoplasmic mislocalization of FUS in both VCP-mutation related ALS and, crucially, in sporadic ALS spinal cord tissue from multiple cases. Furthermore, we provide evidence that FUS protein binds to an aberrantly retained intron within the SFPQ transcript, which is exported from the nucleus into the cytoplasm. Collectively, these data support a model for ALS pathogenesis whereby aberrant intron retention in SFPQ transcripts contributes to FUS mislocalization through their direct interaction and nuclear export. In summary, we report widespread mislocalization of the FUS protein in ALS and propose a putative underlying mechanism for this process.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tyzack</LastName><ForeName>Giulia E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luisier</LastName><ForeName>Raphaelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taha</LastName><ForeName>Doaa M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neeves</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modic</LastName><ForeName>Miha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Jamie S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Ione</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greensmith</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newcombe</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NeuroResource, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ule</LastName><ForeName>Jernej</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luscombe</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Genetics Institute, University College London, Gower Street, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinawa Institute of Science and Technology Graduate University, Okinawa 904-0495, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patani</LastName><ForeName>Rickie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S006591/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>SNSF_</Acronym><Agency>Swiss National Science Foundation</Agency><Country>Switzerland</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2019 Sep 1;142(9):2546-2549</RefSource><PMID Version="1">31497862</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neuropathol Exp Neurol. 2021 Aug 11;80(7):720-722</RefSource><PMID Version="1">33448295</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA binding protein</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">fused in sarcoma FUS</Keyword><Keyword MajorTopicYN="N">intron retention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31368485</ArticleId><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="doi">10.1093/brain/awz217</ArticleId><ArticleId IdType="pii">5542493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Attig J, Agostini F, Gooding C, Chakrabarti AM, Singh A, Haberman N, et al.Heteromeric RNP assembly at LINEs controls lineage-specific RNA processing. Cell 2018; 174: 1067&#x2013;81.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6108849</ArticleId><ArticleId IdType="pubmed">30078707</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4 [Internet]. J Stat Softw 2015; 67: 1&#x2013;48.</Citation></Reference><Reference><Citation>Boeynaems S, Bogaert E, Van Damme P, Van Den Bosch L. Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol 2016; 132: 159&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947127</ArticleId><ArticleId IdType="pubmed">27271576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Qian K, Du Z, Cao J, Petersen A, Liu H, et al.Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell 2014; 14: 796&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230530</ArticleId><ArticleId IdType="pubmed">24704493</ArticleId></ArticleIdList></Reference><Reference><Citation>Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 2010; 19: 1741&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">20147319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CE, Yao Z, Choi M, Tyzack GE, Serio A, Luisier R, et al.Progressive motor neuron pathology and the role of astrocytes in a human stem cell model of VCP-related ALS. Cell Rep 2017; 19: 1739&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5464993</ArticleId><ArticleId IdType="pubmed">28564594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-E, Hong YH, Kim JY, Jeon GS, Jung JH, Yoon B-N, et al.Altered nucleocytoplasmic proteome and transcriptome distributions in an in vitro model of amyotrophic lateral sclerosis. Plos One 2017; 12: e0176462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409181</ArticleId><ArticleId IdType="pubmed">28453527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E, Sandoe J, Williams LA, Boulting GL, Moccia R, Wainger BJ, et al.Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 2014; 14: 781&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Erauskin J, Tadokoro T, Baughn MW, Myers B, McAlonis-Downes M, Chillon-Marinas C, et al.ALS/FTD-Linked mutation in FUS suppresses intra-axonal protein synthesis and drives disease without nuclear loss-of-function of FUS. Neuron 2018; 100: 816&#x2013;30.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6277851</ArticleId><ArticleId IdType="pubmed">30344044</ArticleId></ArticleIdList></Reference><Reference><Citation>Luisier R, Tyzack GE, Hall CE, Mitchell JS, Devine H, Taha DM, et al.Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALS. Nat Commun 2018; 9: 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964114</ArticleId><ArticleId IdType="pubmed">29789581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Wang S, Zheng L, Li X, Suswam EA, Zhang X, et al.Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR). J Biol Chem 2009; 284: 33989&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797169</ArticleId><ArticleId IdType="pubmed">19805546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Zheng L, Viera L, Suswam E, Li Y, Li X, et al.Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J Neurosci 2007; 27: 7929&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672720</ArticleId><ArticleId IdType="pubmed">17652584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al.Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Maffioletti SM, Sarcar S, Henderson ABH, Mannhardt I, Pinton L, Moyle LA, et al.Three-dimensional human iPSC-derived artificial skeletal muscles model muscular dystrophies and enable multilineage tissue engineering. Cell Rep 2018; 23: 899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917451</ArticleId><ArticleId IdType="pubmed">29669293</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al.Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat Methods 2008; 5: 877&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126653</ArticleId><ArticleId IdType="pubmed">18806792</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016; 539: 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al.Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>